Market News
Stay updated with the latest market trends, earnings, and economic indicators.

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
A new-age thirst for beverages is emerging as a key force in India's consumer goods market
Beverage industry in India: Indian companies are seeing strong growth in drinks like coffee, ready-to-drink options, and protein beverages. Younger consumers are driving this trend, seeking convenience and health. Companies are expanding their offerings to meet this demand. This shift presents significant opportunities for future expansion in the Indian beverage market.

Nifty 50, Sensex May Open Muted Ahead of RBI Policy; Titan, Aurobindo Pharma, Groww in Focus - Dalal Street Investment Journal
Nifty 50, Sensex May Open Muted Ahead of RBI Policy; Titan, Aurobindo Pharma, Groww in FocusDalal Street Investment Journal

Sensex Today | Stock Market LIVE Updates: GIFY Nifty hints at gap-down; Ashok Leyland in focus
Sensex Today | Stock Market LIVE Updates: Brent continues to remain below $100 a barrel and the bulls would take that with both hands. For levels, 24,000 continues to act as a barrier for the index, while a close above 23,800 will be crucial to head into the new month on a positive note.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.
Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs
Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.
Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks
The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.
Sensex dives 850 pts, Nifty slips below 24,200 amid oil shock and weak global cues
The equity benchmark indices Sensex and Nifty tumbled on Thursday, extending losses for a second straight session. Firm crude oil prices and ongoing geopolitical tensions rattled sentiment. Brent crude surged for the fourth consecutive day to around $103 per barrel amid uncertainty over US-Iran talks and fresh concerns around the Strait of Hormuz. Weak Asian cues and persistent foreign fund outflows deepened the sell-off. The Nifty slipped below the 24,200 mark, dragged by auto, PSU banks and consumer durables stocks, while pharma and healthcare shares saw selective buying. Investors stayed cautious, closely tracking the ongoing Q4 earnings season for further triggers.

CLSA says Nifty has given a new signal on the charts; check potential returns and top midcap 'buys'
Laurence Balanco of CLSA has shared five midcap ideas: BSE, MCX, Apollo Tubes, Dixon Technologies and Aurobindo Pharma.